Advertisement

Doxazosin Tablets

[01 May 2014]

Products Affected - Description

Doxazosin tablets

Reason for the Shortage

Teva discontinued all unit-dose presentations in November, 2012.

Available Products

Doxazosin caplets, Apotex
1 mg, 100 count (NDC 60505-0093-00)
1 mg, 1000 count (NDC 60505-0093-01)
2 mg, 100 count (NDC 60505-0094-00)
2 mg, 1000 count (NDC 60505-0094-01)
4 mg, 100 count (NDC 60505-0095-00)
4 mg, 1000 count (NDC 60505-0095-01)
8 mg, 100 count (NDC 60505-0096-00)
8 mg, 1000 count (NDC 60505-0096-01)
 
Doxazosin tablets, Dava
1 mg, 100 count (NDC 67253-0380-10)
2 mg, 100 count (NDC 67253-0381-10)
4 mg, 100 count (NDC 67253-0382-10)
8 mg, 100 count (NDC 67253-0383-10)
 
Doxazosin tablets, Mylan
1 mg, 100 count (NDC 00378-4021-01)
2 mg, 100 count (NDC 00378-4022-01)
4 mg, 100 count (NDC 00378-4024-01)
8 mg, 100 count, NDC 00378-4028-01 
 
Doxazosin tablets, UDL
1 mg, 100 count, unit dose (NDC 51079-0957-20)
2 mg, 100 count, unit dose (NDC 51079-0958-20)
4 mg, 100 count, unit dose (NDC 51079-0959-20)
 
Cardura tablets, Pfizer
1 mg, 100 count (NDC 00049-2750-66)
2 mg, 100 count (NDC 00049-2760-66)
4 mg, 100 count (NDC 00049-2770-66)
8 mg, 100 count (NDC 00049-2780-66)

Cardura XL tablets, Pfizer
4 mg, 100 count (NDC 00049-2710-30) 8 mg, 100 count (NDC 00049-2720-30)
 
Doxazosin tablets, Teva
1 mg, 100 count (NDC 00093-8120-01)
2 mg, 100 count (NDC 00093-8121-01)
4 mg, 100 count (NDC 00093-8122-01)
8 mg, 100 count (NDC 00093-8123-01)

Estimated Resupply Dates

All presentations are currently available.

Related Shortages

Updated

May 1, 2014; February 27, 2014; January 29, 2014; January 8, 2014; November 13, 2013; August 29, 2013; August 5, 2013; August 1, 2013; July 3, 2013; April 23, 2013; March 29, 2013; March 4, 2013; January 30, 2013; December 21, 2012; December 7, 2012; November 2, 2012; September 17, 2012. University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement